Search
Longeveron Inc
LGVNAdd to Watchlist
0.729USD
+0.026+3.71%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
22.44MMarket Cap
LossP/E TTM
More Details of Longeveron Inc Company
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Longeveron Inc Info
Ticker SymbolLGVN
Company nameLongeveron Inc
IPO dateFeb 12, 2021
CEOPowell (Than)
Number of employees25
Security typeOrdinary Share
Fiscal year-endFeb 12
Address1951 NW 7th Ave
CityMIAMI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33136
Phone13053027158
Websitehttps://www.longeveron.com/
Ticker SymbolLGVN
IPO dateFeb 12, 2021
CEOPowell (Than)
Company Executives of Longeveron Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
355.14K
+70.39%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
342.88K
+72.91%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
302.11K
+82.75%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
256.46K
+2.07%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
24.92K
--
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+76.12%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
13.58K
--
Mr. Rock Soffer
Mr. Rock Soffer
Director
Director
--
--
Mr. Paul Lehr, J.D.
Mr. Paul Lehr, J.D.
General Counsel and Secretary
General Counsel and Secretary
--
--
Mr. Than Powell
Mr. Than Powell
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
355.14K
+70.39%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
342.88K
+72.91%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
302.11K
+82.75%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
256.46K
+2.07%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
24.92K
--
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+76.12%
FAQs
Who are the top five shareholders of Longeveron Inc?
The top five shareholders of Longeveron Inc are: Ms. Lisa Locklear
How many institutions hold shares of Longeveron Inc (LGVN)?
As of 2026Q1, 62 institutions hold shares of Longeveron Inc, with a combined market value of approximately 2.25M, accounting for 8.08% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1131825.00.
What is the biggest source of revenue for Longeveron Inc?
In 2026Q1, the Clinical trial revenue business generated the highest revenue for Longeveron Inc, amounting to 954.00K and accounting for 79.57% of total revenue.